MX9304363A - Metodo para enlace intracelular de moleculas blanco. - Google Patents

Metodo para enlace intracelular de moleculas blanco.

Info

Publication number
MX9304363A
MX9304363A MX9304363A MX9304363A MX9304363A MX 9304363 A MX9304363 A MX 9304363A MX 9304363 A MX9304363 A MX 9304363A MX 9304363 A MX9304363 A MX 9304363A MX 9304363 A MX9304363 A MX 9304363A
Authority
MX
Mexico
Prior art keywords
target
antibody
intracellular
linking
binding
Prior art date
Application number
MX9304363A
Other languages
English (en)
Inventor
Wayne A Marasco
William A Haseltine
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of MX9304363A publication Critical patent/MX9304363A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072Regulatory proteins, e.g. tat, rev, vpt
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/80Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/81Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the endoplasmatic reticulum [ER] or the Golgi apparatus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/80Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe un método para el enlace intracelular de moléculas específicas, preferentemente proteínas. De manera más específica, este método implica la expresión intracelular y el uso subsecuentemente de anticuerpos específicos para una molécula deseada.
MX9304363A 1992-07-17 1993-07-19 Metodo para enlace intracelular de moleculas blanco. MX9304363A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91693992A 1992-07-17 1992-07-17
US4527493A 1993-03-31 1993-03-31

Publications (1)

Publication Number Publication Date
MX9304363A true MX9304363A (es) 1994-02-28

Family

ID=26722587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304363A MX9304363A (es) 1992-07-17 1993-07-19 Metodo para enlace intracelular de moleculas blanco.

Country Status (10)

Country Link
US (4) US6004940A (es)
EP (1) EP0651805B1 (es)
CN (1) CN1084216A (es)
AT (1) ATE348175T1 (es)
AU (1) AU687010B2 (es)
CA (1) CA2137558A1 (es)
DE (1) DE69334095T2 (es)
MX (1) MX9304363A (es)
PT (1) PT651805E (es)
WO (1) WO1994002610A1 (es)

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2137558A1 (en) * 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
IL107026A0 (en) * 1992-09-16 1993-12-28 Univ Tennessee Res Corp Antigen of hybrid m protein and carrier for group a streptococcal vaccine
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
CA2168349A1 (en) * 1993-07-30 1995-02-09 Lingxun Duan Intracellular immunization
JPH10501681A (ja) * 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6451995B1 (en) * 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
EP0934083B1 (en) * 1996-10-23 2009-04-29 The Trustees Of The University Of Pennsylvania Improved vaccines
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
AP1313A (en) 1996-12-06 2004-10-04 Aventis Pharma Inc Polypeptides encoded by a human lipase-like gene, composition and method.
EP1015616A2 (en) * 1997-09-19 2000-07-05 Dana Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
US6077676A (en) * 1997-12-18 2000-06-20 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
PT1049767E (pt) 1998-01-08 2005-10-31 Agronomique Inst Nat Rech Coelho transgenico que expressa uma lipoproteina (a) humana funcional
IL147972A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Ge Pd-1, a receptor for b7-4 and uses therefor
WO2001021800A1 (en) * 1999-09-20 2001-03-29 Aberdeen University Monoclonal antibody 3f1h10 neutralising vhsv (viral haemorrhagic septicaemia virus)
US20030049251A1 (en) * 1999-12-08 2003-03-13 Barbas Carlos F. Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
US7078486B2 (en) 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
MXPA02006433A (es) 1999-12-30 2002-11-29 Harvard College Metodos y composiciones que se refieren a la modulacion del crecimiento de hepatocitos, diferenciacion de celulas plasmaticas o actividad de subgrupos de celulas t mediante la modulacion de la actividad de xbp-1.
US6291652B1 (en) 2000-01-07 2001-09-18 The Regents Of The University Of California Antibodies specific for proteins having polyglutamine expansions
ATE486089T1 (de) 2000-03-31 2010-11-15 Aventis Pharma Inc Nuklearfaktor kb induzierender faktor
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
AU2001262960A1 (en) * 2000-04-28 2001-11-12 Zengen, Inc. New antibodies to biological membranes
US6410246B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
US6406863B1 (en) * 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
CA2442066C (en) 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
JP4423542B2 (ja) * 2002-04-25 2010-03-03 東亞合成株式会社 抗菌性ポリペプチド及びその利用
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7638134B2 (en) 2003-02-20 2009-12-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Insertion sites in fowlpox vectors
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
WO2005049819A1 (ja) 2003-10-29 2005-06-02 Toagosei Co., Ltd. 抗菌ペプチド及びその利用
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
JP4507080B2 (ja) 2004-07-30 2010-07-21 東亞合成株式会社 抗菌ペプチド及びその利用
CA2583017A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060147997A1 (en) * 2004-11-30 2006-07-06 Virosys Pharmaceuticals, Inc. PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
CA2597325A1 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
US7807162B2 (en) 2005-05-20 2010-10-05 Ablynx N.V. Single domain VHH antibodies against von Willebrand factor
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
CA2630964A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2325208B1 (en) 2005-12-15 2017-09-20 Genentech, Inc. Polyubiquitin antibodies
GB0605584D0 (en) * 2006-03-20 2006-04-26 Olink Ab Method for analyte detection using proximity probes
JP2009536527A (ja) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
WO2008008284A2 (en) 2006-07-14 2008-01-17 The Regents Of The University Of California Cancer biomarkers and methods of use threof
EP2115004A2 (en) 2006-12-19 2009-11-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR20100115346A (ko) 2007-12-06 2010-10-27 다나-파버 캔서 인스티튜트 인크. 인플루엔자 바이러스에 대한 항체 및 그의 이용 방법
EP2947097A1 (en) 2008-04-07 2015-11-25 Ablynx N.V. Amino acid sequences directed against the Notch pathways and uses thereof
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
CN102224254A (zh) 2008-09-23 2011-10-19 哈佛大学校长及研究员协会 Sirt4及其用途
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
US8535681B2 (en) * 2008-10-16 2013-09-17 Kathleen Cogan Farinas Sustained drug delivery system
CN104689316A (zh) 2008-10-22 2015-06-10 弗·哈夫曼-拉罗切有限公司 轴突变性的调节
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
CA2740192C (en) 2008-12-01 2019-12-31 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US9599591B2 (en) 2009-03-06 2017-03-21 California Institute Of Technology Low cost, portable sensor for molecular assays
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
RU2539798C2 (ru) 2009-04-10 2015-01-27 Аблинкс Нв Улучшенные аминокислотные последовательности против il-6r и содержащие их полипептиды для лечения связанных с il-6r заболеваний и нарушений
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
CN104043126A (zh) 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
JP2013509874A (ja) 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
EP2499159B1 (en) 2009-11-13 2017-01-04 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
HUE027713T2 (en) 2009-12-23 2016-10-28 Hoffmann La Roche Anti-BV8 antibodies and their use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US20120294857A1 (en) * 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
GB201004292D0 (en) * 2010-03-15 2010-04-28 Olink Ab Assay for localised detection of analytes
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
EP2561356B1 (en) 2010-04-18 2016-08-03 Yeda Research and Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US20120003639A1 (en) 2010-04-27 2012-01-05 Prelude, Inc. Cancer biomarkers and methods of use thereof
WO2011143262A2 (en) 2010-05-10 2011-11-17 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
GB201011971D0 (en) 2010-07-15 2010-09-01 Olink Ab Methods and product
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
ES2588981T3 (es) 2010-10-05 2016-11-08 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
EP2627781B1 (en) 2010-10-15 2017-02-22 Olink Bioscience AB Dynamic range methods
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Cxcr2結合ポリペプチド
EP2466310A1 (en) 2010-12-17 2012-06-20 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Means and methods for detecting double-strand breaks
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
GB201107863D0 (en) 2011-05-11 2011-06-22 Olink Ab Method and product
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
GB201201547D0 (en) 2012-01-30 2012-03-14 Olink Ab Method and product
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013249985B2 (en) 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
WO2014022759A1 (en) 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
RU2631002C2 (ru) * 2012-12-05 2017-09-15 Тевакс Дженетикс Вэксин Ко., Лтд. Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
ES2674704T3 (es) 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Inmunoensayos de posaconazol
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
CA2901513C (en) 2013-03-12 2020-12-29 Ventana Medical Systems, Inc. Proximity assay for in situ detection of targets
WO2014139979A1 (en) 2013-03-12 2014-09-18 Ventana Medical Systems, Inc. Quantum dot in situ hybridization
AU2014236882B2 (en) 2013-03-14 2019-01-31 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
CA2913490A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of cancer using pd-l1 isoforms
AU2014278833A1 (en) 2013-06-13 2016-01-07 Fast Forward Pharmaceuticals B.V. CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
AU2014296288B2 (en) 2013-07-31 2020-02-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
KR20210123433A (ko) 2013-08-29 2021-10-13 시티 오브 호프 세포침투 콘주게이트 및 이의 사용 방법
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
CN105764921B (zh) 2013-09-17 2020-06-30 台湾浩鼎生技股份有限公司 用于诱导免疫反应的糖疫苗组合物及其治疗癌症的用途
EP3521431A1 (en) 2013-09-25 2019-08-07 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗her2糖操作抗体群およびその使用
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102576850B1 (ko) 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-tnf-알파 글리코항체 및 이의 용도
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
JP2017522884A (ja) * 2014-07-29 2017-08-17 ファイザー・インク がん免疫療法のためのEGFRvIII特異的キメラ抗原受容体
JP6899321B2 (ja) 2014-09-08 2021-07-07 アカデミア シニカAcademia Sinica 糖脂質を使用するヒトiNKT細胞活性化
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
US9695234B2 (en) * 2014-10-23 2017-07-04 Singh Molecular Medicine, Llc Single domain antibodies directed against STAT3
CN107207587B (zh) 2014-11-05 2022-04-19 安尼艾克松股份有限公司 人源化抗-补体因子c1q抗体及其应用
US20180042994A1 (en) 2014-11-17 2018-02-15 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
WO2016090323A1 (en) 2014-12-05 2016-06-09 Prelude, Inc. Dcis recurrence and invasive breast cancer
US11220545B2 (en) 2014-12-08 2022-01-11 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
KR102630294B1 (ko) 2015-01-24 2024-01-26 아카데미아 시니카 암 마커 및 이를 사용하는 방법
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
KR102620346B1 (ko) 2015-01-30 2024-01-02 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
JP2018512597A (ja) 2015-02-04 2018-05-17 ジェネンテック, インコーポレイテッド 突然変異体スムースンド及びその使用方法
EP3761036A1 (en) 2015-03-03 2021-01-06 ARK Diagnostics, Inc. Pregabalin immunoassays
US20180042998A1 (en) 2015-03-10 2018-02-15 University Of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3294280A1 (en) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrin inhibitors for the treatment of cancer
PL3294768T3 (pl) 2015-05-13 2020-03-31 Ablynx N.V. Polipeptydy rekrutujące komórki T oparte na reaktywności TCR alfa/beta
SI3294319T1 (sl) 2015-05-13 2024-09-30 Ablynx Nv Polipeptidi, ki rekrutirajo celice T na osnovi reaktivnosti CD3
EP3344806A4 (en) 2015-09-04 2019-03-20 OBI Pharma, Inc. GLYCAN NETWORKS AND METHODS OF USE
EP3362074B1 (en) 2015-10-16 2023-08-09 President and Fellows of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
WO2017122203A1 (en) 2016-01-11 2017-07-20 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
RU2751662C2 (ru) 2016-01-21 2021-07-15 Пфайзер Инк. Химерные антигенные рецепторы, нацеливающиеся на вариант iii рецептора эпидермального фактора роста
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
SG11201807437XA (en) 2016-03-01 2018-09-27 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific to human poliovirus receptor (pvr)
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカAcademia Sinica N−グリカンおよびそのアレイのモジュール合成のための方法
WO2017172990A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
AU2017252128B2 (en) 2016-04-22 2024-06-06 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
CN106267409B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物治疗反应器
CN106178163B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物细胞免疫治疗仪
EP3490592A4 (en) 2016-07-27 2020-03-25 OBI Pharma, Inc. IMMUNOGENIC / THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF
TWI786054B (zh) 2016-07-29 2022-12-11 台灣浩鼎生技股份有限公司 人類抗體、醫藥組合物、及其方法
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
CA3034643A1 (en) 2016-09-20 2018-03-29 Ellen Weisberg Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
WO2018091606A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
TWI767959B (zh) 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
EP3634991A1 (en) 2017-05-23 2020-04-15 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
EP3704156A1 (en) * 2017-11-03 2020-09-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
US20210147487A1 (en) * 2018-04-04 2021-05-20 The University Of North Carolina At Chapel Hill Methods and compositions for engineered assembly activating proteins (eaaps)
US20220125891A1 (en) 2018-06-06 2022-04-28 Osaka University Method for treating and/or preventing regnase-1-related disease
US20210255189A1 (en) 2018-06-15 2021-08-19 Olink Proteomics Ab Biomarker panel for ovarian cancer
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
JP2022500504A (ja) 2018-09-14 2022-01-04 プレリュード コーポレーションPrelude Corporation 浸潤性乳癌のリスクを有する対象の治療の選択方法
US20220033519A1 (en) * 2018-09-21 2022-02-03 National Research Council Of Canada Intrabodies for reducing fut8 activity
EP3962529A4 (en) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. METHOD FOR CANCER TREATMENT USING ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKING REAGENTS COMBINATIONS
WO2020245663A1 (en) 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
EP4096647A1 (en) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Treating acute liver disease with tlr-mik inhibitors
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling the ubiquitination process of mlkl for disease treatment
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
EP4291175A1 (en) 2021-02-11 2023-12-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancers using sting agonists
IL305301A (en) 2021-02-19 2023-10-01 Us Health Single domain antibodies neutralizing SARS CoV-2
IL305575A (en) 2021-03-02 2023-10-01 Dana Farber Cancer Inst Inc Methods for treating red blood cell disorders
EP4319800A1 (en) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
US20240280561A1 (en) 2021-06-08 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023091704A1 (en) 2021-11-18 2023-05-25 Circularis Biotechnologies, Inc. Compositions and methods for production of circular nucleic acid molecules
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024156899A1 (en) 2023-01-27 2024-08-02 Biomerieux Modified immuno-molecular assay for faster biomarker detection
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005250A1 (en) * 1990-09-25 1992-04-02 University Of Connecticut Prolonging expression of polynucleotides introduced into a cell
JP3512795B2 (ja) * 1991-09-30 2004-03-31 アメリカ合衆国 組換免疫毒素
EP0618970A1 (en) * 1991-12-10 1994-10-12 Dana Farber Cancer Institute Reactive neutralizing human anti-gp120 recombinant antibody, dna coding the same and use thereof
CA2137558A1 (en) * 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules

Also Published As

Publication number Publication date
ATE348175T1 (de) 2007-01-15
US5965371A (en) 1999-10-12
US6004940A (en) 1999-12-21
US6329173B1 (en) 2001-12-11
WO1994002610A1 (en) 1994-02-03
EP0651805A1 (en) 1995-05-10
PT651805E (pt) 2007-02-28
DE69334095T2 (de) 2007-04-12
CN1084216A (zh) 1994-03-23
AU687010B2 (en) 1998-02-19
AU4775393A (en) 1994-02-14
DE69334095D1 (de) 2007-01-25
US6072036A (en) 2000-06-06
EP0651805B1 (en) 2006-12-13
CA2137558A1 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
MX9304363A (es) Metodo para enlace intracelular de moleculas blanco.
Caskey et al. Translation: its mechanism and control
BR9713294A (pt) "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
EP0930366A3 (en) Binding domains in delta proteins
DE69434166D1 (de) Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
KR950700419A (ko) 단량체 및 이량체 항체-단편 융합 단백질(monomeric and dimeric antibody-fragment fusion proteins)
HUS1400027I1 (hu) OBM elleni antitestek
BR9707379A (pt) Anticorpo humano isolado ácido nucleico isolado vetor recombinante de expressão célula hospedeira processo para sintetizar um anticorpo humano que se liga á TNF Alfa humano composição farmacéutica processo para inibir á atividade do TNF humano e uso do anticorpo
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
ATE159429T1 (de) Methode zum überbringen von agenzien an zielzellen
FI925986A (fi) Slumpartat bio-oligomer bibliotek, ett foerfarande foer syntetisering avdet samt ett foerfarande foer anvaendning av det
UA102988C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕН-СВЯЗЫВАЮЩАЯ ЧАСТЬ, КОТОРАЯ СВЯЗЫВАЕТ TNFα ЧЕЛОВЕКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, В КОТОРОМ АКТИВНОСТЬ TNFα ЯВЛЯЕТСЯ ВРЕДНОЙ
CY1112101T1 (el) Νευροτροφικοι παραγοντες
EE05496B1 (et) Antikeha, mis seob osteoprotegeriini siduvat valku
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
PT2305715T (pt) Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
DK0590071T3 (da) Hovedsagelig rene receptor-lignende TGF-BETA-1 bindende molekyler samt anvendelse deraf
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
NZ504752A (en) Hydrophobically-modified protein compositions (particularly hedgehog proteins)
NZ296748A (en) Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
FI956057A (fi) Solunsisäisiä sitoutumisproteiineja (PIL) ja niiden käytöt
ATE332914T1 (de) Mimotope und antimimotope des menschlichen plättchen-glykoproteins ib/ix
DE69535789D1 (de) Il-2r-assoziiertes polypeptid und dafür kodierende dna-molekülen
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees